NL-OMON54621招募中不适用
Prospective Bladder Cancer Infrastructure - An infrastructure for observational and interventional bladder cancer research - ProBCI
Stichting Prospectieve Blaaskanker Infrastructuur0 个研究点目标入组 3,500 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 3,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologically proven bladder cancer (high-risk non-muscle-invasive /
- •muscle-invasive / metastatic)
- •Written informed consent
排除标准
- •Bladder cancer stage Ta
- •Inable to read and understand informed consent procedure
- •No inhabitant of the Netherlands
研究者
相似试验
招募中
不适用
Prospective Bladder Cancer Infrastructure (ProBCI)Bladder CancerNCT04503577Prospective Bladder Cancer Infrastructure Foundation3,600
招募中
不适用
BlaaskankerZorg In BeeldBladder cancerNL-OMON26633Dutch Cancer Society (KWF Kankerbestrijding)6,500
尚未招募
不适用
Xpert Bladder Cancer Monitorto Predict Need for 2nd TURBMoniTURB Trial”C67Malignant neoplasm of bladderDRKS00014974Cepheid Europe600
尚未招募
不适用
Bladder cancer sentinel node mapping using ICG-99mTc-nanocolloidBladder cancerBladder carcinomaNL-OMON21640The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands30
进行中（未招募）
不适用
Detection of bladder cancer using a fluorescent dye (PVP-Hypericin)Suspected non-muscle invasive (superficial) bladder cancerMedDRA version: 17.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001819-30-DESanochemia Pharmazeutika AG220